Bristol Myers Squibb
BREYANZI
Manufacturer:
Bristol Myers Squibb
Name:
BREYANZI
HCPCS Code Descriptor:
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2054
NDC(s):
73153-0900-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
BREYANZI is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The Q Code: Q2054 is aligned to the drug BREYANZI.